<DOC>
	<DOCNO>NCT01229176</DOCNO>
	<brief_summary>This phase 2 trial aim obtain information safety immunogenicity Vi-CRM197 subject various age group India Pakistan Typhoid Fever highly endemic efficacious vaccine disease much need .</brief_summary>
	<brief_title>Safety Immunogenicity Vi-CRM197 Vaccine Against S. Typhi Adults , Children , Older Infants Infants</brief_title>
	<detailed_description />
	<mesh_term>Typhoid Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Main eligibility criterion : Subjects belong 4 age group enrol trial : adult ( 18 45 year age ) , child ( 24 59 month age ) , old infant ( 9 12 month age enrollment ) infant ( 6 week age enrolment ) . Written inform consent obtain subject parents/ guardian ( depend age group ) enrollment trial . Only females negative pregnancy test willing participate family planning consultation ( organize site study team ) allow participate trial . Infants vaccinate 1 dose BCG , HBV OPV birth enrol trial , infant receive DTwP+HBV+Hib OPV due 6 week age per local EPI schedule enrol trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>